| Down syndrome SE Antonarakis, BG Skotko, MS Rafii, A Strydom, SE Pape, DW Bianchi, ... Nature Reviews Disease Primers 6 (1), 9, 2020 | 847 | 2020 |
| Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup CR Jack Jr, JS Andrews, TG Beach, T Buracchio, B Dunn, A Graf, ... Alzheimer's & Dementia 20 (8), 5143-5169, 2024 | 420 | 2024 |
| Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial S Craft, R Raman, TW Chow, MS Rafii, CK Sun, RA Rissman, ... JAMA neurology 77 (9), 1099-1109, 2020 | 321 | 2020 |
| Recent developments in Alzheimer's disease therapeutics MS Rafii, PS Aisen BMC medicine 7, 1-4, 2009 | 284 | 2009 |
| A phase II trial of huperzine A in mild to moderate Alzheimer disease MS Rafii, S Walsh, JT Little, K Behan, B Reynolds, C Ward, S Jin, ... Neurology 76 (16), 1389-1394, 2011 | 260 | 2011 |
| A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease MS Rafii, TL Baumann, RAE Bakay, JM Ostrove, J Siffert, AS Fleisher, ... Alzheimer's & dementia 10 (5), 571-581, 2014 | 237 | 2014 |
| Agrin and microvascular damage in Alzheimer’s disease TM Berzin, BD Zipser, MS Rafii, V Kuo—Leblanc, GD Yancopouloš, ... Neurobiology of aging 21 (2), 349-355, 2000 | 219 | 2000 |
| Adeno-associated viral vector (serotype 2)–nerve growth factor for patients with alzheimer disease: a randomized clinical trial MS Rafii, MH Tuszynski, RG Thomas, D Barba, JB Brewer, RA Rissman, ... JAMA neurology 75 (7), 834-841, 2018 | 217 | 2018 |
| Alzheimer's disease associated with Down syndrome: a genetic form of dementia J Fortea, SH Zaman, S Hartley, MS Rafii, E Head, M Carmona-Iragui The Lancet Neurology 20 (11), 930-942, 2021 | 214 | 2021 |
| Trial of solanezumab in preclinical Alzheimer’s disease RA Sperling, MC Donohue, R Raman, MS Rafii, K Johnson, CL Masters, ... New England Journal of Medicine 389 (12), 1096-1107, 2023 | 176 | 2023 |
| A phase 3 trial of IV immunoglobulin for Alzheimer disease NR Relkin, RG Thomas, RA Rissman, JB Brewer, MS Rafii, CH Van Dyck, ... Neurology 88 (18), 1768-1775, 2017 | 173 | 2017 |
| Outcome measures for clinical trials in Down syndrome AJ Esbensen, SR Hooper, D Fidler, SL Hartley, J Edgin, XL d'Ardhuy, ... American journal on intellectual and developmental disabilities 122 (3), 247-281, 2017 | 149 | 2017 |
| High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment S Kovacevic, MS Rafii, JB Brewer, ... Alzheimer Disease & Associated Disorders 23 (2), 139-145, 2009 | 144 | 2009 |
| Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial CH Van Dyck, HB Nygaard, K Chen, MC Donohue, R Raman, ... JAMA neurology 76 (10), 1219-1229, 2019 | 141 | 2019 |
| The AHEAD 3‐45 Study: design of a prevention trial for Alzheimer's disease MS Rafii, RA Sperling, MC Donohue, J Zhou, C Roberts, MC Irizarry, ... Alzheimer's & dementia 19 (4), 1227-1233, 2023 | 138 | 2023 |
| Agrin in Alzheimer’s disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma JE Donahue, TM Berzin, MS Rafii, DJ Glass, GD Yancopoulos, JR Fallon, ... Proceedings of the National Academy of Sciences 96 (11), 6468-6472, 1999 | 133 | 1999 |
| Advances in Alzheimer’s disease drug development MS Rafii, PS Aisen BMC medicine 13 (1), 62, 2015 | 131 | 2015 |
| The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual … JA Moran, MS Rafii, SM Keller, BK Singh, MP Janicki Mayo Clinic Proceedings 88 (8), 831-840, 2013 | 114 | 2013 |
| Early-stage Alzheimer disease: getting trial-ready PS Aisen, GA Jimenez-Maggiora, MS Rafii, S Walter, R Raman Nature Reviews Neurology 18 (7), 389-399, 2022 | 110 | 2022 |
| Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial R Sperling, D Henley, PS Aisen, R Raman, MC Donohue, K Ernstrom, ... JAMA neurology 78 (3), 293-301, 2021 | 104 | 2021 |
Michael C Donohue, PhDAssociate Director of Biostatistics, Alzheimer's Therapeutic Research Institute, USCPreverjeni e-poštni naslov na usc.edu